STOCK MARKET BSE NSE

Oncology, BT’s next focus?

Published: 11th June 2012 11:11 AM  |   Last Updated: 11th June 2012 11:11 AM   |  A+A-

Following studies showing that cancer cases in India may rise to up to 78 per cent by 2030, oncology is all set to receive focus in Biopharmaceutical research, said experts.

At a seminar on Biotechnology and Bio Pharmaceuticals at the recently concluded GIM-2102, managing director of Evolva Biotech P M Murali said that in the future  oncology will fuel research in India.

“We have the largest number of head and neck cancer cases. The pharmaceutical industry will have to attend to this growing number and so research in the sector will rise,” he said. Murali added affordability will be the mantra for research in India.

Kiran Mazumdar Shaw of  Biocon said, The field of oncology research is extremely important. There are some key areas like diagnostics that are of crucial importance.”  Murali also added that the Central government was making efforts to frame policies which would make India the hub of biomanufacturing.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp